PD-1 Antagonist and Eribulin Combination Therapy for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for breast cancer and melanoma, face challenges in effectively targeting and overcoming the immune evasion mechanisms mediated by the PD-1/PD-L1 pathway, leading to impaired immune responses against tumors.
Innovation Solution
A combination therapy involving a PD-1 antagonist, such as a monoclonal antibody, and eribulin or its pharmaceutically acceptable salt, is administered to inhibit the PD-1/PD-L1 interaction, enhancing anti-tumor immune responses in breast cancer and melanoma patients, especially those with elevated PD-L1 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/PD-L1 pathway is targeted to enhance immune response, then anti-tumor immune response is improved, but immune evasion mechanisms remain effective
Solution Approach 1:
The patent combines PD-1 pathway inhibition with eribulin chemotherapy to create a synergistic effect. The PD-1 antagonist (nivolumab or pembrolizumab) blocks immune evasion, while eribulin enhances immune activation through microtubule disruption, together providing more reliable anti-tumor response than either agent alone
2Reliability
If combination therapy with PD-1 antagonist and eribulin is used, then treatment efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent establishes predetermined dosing schedules and administration protocols for the combination therapy. Eribulin is administered at 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, with PD-1 antagonists given according to their approved regimens. This preliminary planning simplifies the complexity by providing clear, pre-established treatment parameters
3Reliability
If eribulin is administered at standard dosage, then anti-cancer activity is maintained, but immune activation is insufficient
Solution Approach 1:
The patent leverages the dual mechanism of eribulin: its standard dosing maintains anti-cancer activity through microtubule disruption, while its immunomodulatory effects (enhancing dendritic cell function, increasing cytokine production) are amplified when combined with PD-1 pathway inhibition, achieving sufficient immune activation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy effectively boosts anti-tumor responses by blocking the PD-1/PD-L1 pathway, improving treatment outcomes for metastatic and triple-negative breast cancer, and melanoma by increasing immune activation against cancer cells.
Implementation Method 1
the PD-1 antagonist is a monoclonal antibody, or an antigen binding fragment thereof, which specifically binds to PD-1 or to PD-L1 and blocks the binding of PD-L1 to PD-1
Data Source
AI summary
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.